Magnetic Fields Cancer Research Results

MF, Magnetic Fields: Click to Expand ⟱
Features: Therapy
Magnetic Fields can be Static, or pulsed. The most common therapy is a pulsed magnetic field in the uT or mT range.
The main pathways affected are:
Calcium Signaling: -influence the activity of voltage-gated calcium channels.
Oxidative Stress and Reactive Oxygen Species (ROS) Pathways
Heat Shock Proteins (HSPs) and Cellular Stress Responses
Cell Proliferation and Growth Signaling: MAPK/ERK pathway.
Gene Expression and Epigenetic Modifications: NF-κB
Angiogenesis Pathways: VEGF (improving VEGF for normal cells)
PEMF was found to have a 2-fold increase in drug uptake compared to traditional electrochemotherapy in rat melanoma models

Pathways:
- most reports have ROS production increasing in cancer cells , while decreasing in normal cells.
- ROS↑ related: MMP↓(ΔΨm), ER Stress↑, UPR↑, GRP78↑, Ca+2↑, Cyt‑c↑, Caspases↑, DNA damage↑, cl-PARP↑, HSP↓, Prx,
- Raises AntiOxidant defense in Normal Cells: ROS↓, NRF2↑, SOD↑, GSH↑, Catalase↑,
- lowers Inflammation : NF-kB↓, COX2↓, Pro-Inflammatory Cytokines : NLRP3↓, IL-1β↓, TNF-α↓, IL-6↓, IL-8↓
- inhibit Growth/Metastases : TumMeta↓, TumCG↓, VEGF↓(mostly regulated up in normal cells),
- cause Cell cycle arrest : TumCCA↑,
- inhibits Migration/Invasion : TumCMig↓, TumCI↓, TNF-α↓,
- inhibits glycolysis /Warburg Effect and ATP depletion : HIF-1α↓, PKM2↓, GLUT1↓, LDH↓, HK2↓, PFKs↓, PDKs↓, ECAR↓, OXPHOS↓, GRP78↑, Glucose↓, GlucoseCon↓
- inhibits angiogenesis↓ : VEGF↓, HIF-1α↓, Notch↓, FGF↓, PDGF↓, EGFR↓, Integrins↓,
- Others: PI3K↓, AKT↓, STAT↓, Wnt↓, β-catenin↓, ERK↓, JNK, - SREBP (related to cholesterol).
- Synergies: chemo-sensitization, chemoProtective, cytoProtective, RadioSensitizer, RadioProtective, Others(review target notes), Neuroprotective, Hepatoprotective, CardioProtective,

- Selectivity: Cancer Cells vs Normal Cells

Non-Static Magnetic Fields (AC / Pulsed / Oscillating MF)
Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Reactive oxygen species (ROS) ↑ ROS (P→R); often sustained (G) ↑ ROS (P); ↔/↓ net ROS (R→G) P, R, G Upstream redox perturbation MF perturbs electron/radical dynamics: normal cells often adapt (ROS setpoint ↓), cancer cells less so
2 NRF2 antioxidant response ↔ / insufficient NRF2 induction (R→G) ↑ NRF2 activation (R→G) R, G Adaptive redox defense Explains mixed ROS direction in normal cells (initial ↑ then adaptive ↓)
3 Glutathione (GSH) homeostasis ↓ GSH (R→G) ↔ or transient ↓ (R) with recovery (G) R, G Redox buffering capacity GSH depletion reflects sustained oxidative load; recovery indicates successful adaptation
4 Superoxide dismutase (SOD) / antioxidant enzymes ↔ or inadequate enzyme upshift (G) ↑ SOD/GPx/CAT capacity (G) G Longer-term antioxidant remodeling Often the “endpoint” readout that correlates with ROS-normalization in normal tissue
5 Mitochondrial ETC / respiration ↓ ETC efficiency; ↑ electron leak (P→R) ↔ mild, reversible ETC perturbation (P→R) P, R Bioenergetic destabilization ETC perturbation is a mechanistic bridge between MF exposure and ROS/ΔΨm changes
6 Mitochondrial membrane potential (ΔΨm / MMP) ↓ ΔΨm (R); may progress (G) ↔ preserved or reversible dip (R) R, G Mitochondrial dysfunction thresholding ΔΨm loss typically follows ROS/ETC disruption rather than preceding it
7 Ca²⁺ signaling (VGCC / ER–mitochondria Ca²⁺ flux) ↑ dysregulated Ca²⁺ influx/transfer (P→R); overload may persist (G) ↑ transient Ca²⁺ signaling (P); homeostasis restored (R→G) P, R, G Stress signal amplification Ca²⁺ dysregulation links ROS/ETC perturbation to ER stress and mitochondrial dysfunction (amplifies ΔΨm loss and UPR commitment)
8 Mitochondrial permeability transition pore (MPTP) ↑ MPTP opening propensity (R); sustained opening possible (G) ↔ transient or closed (R→G) P, R, G Commitment point for mitochondrial failure MPTP opening integrates ROS, Ca²⁺ overload, and ΔΨm loss; acts as a threshold event converting reversible stress into irreversible mitochondrial dysfunction
9 ER stress / UPR ↑ ER stress (R); CHOP-commitment possible (G) ↑ adaptive UPR (R); resolves (G) R, G Proteostasis stress Often downstream of ROS + Ca²⁺ handling perturbations
10 DNA damage (oxidative) ↑ damage markers (R→G) ↔ or repaired (G) R, G Checkpoint pressure Generally secondary to ROS; interpret as stress consequence not “direct genotoxicity”
11 LDH / glycolytic flux ↓ glycolytic performance (R→G) ↔ flexible substrate switching (R→G) R, G Metabolic vulnerability Redox imbalance can destabilize high-rate glycolysis in cancer-biased contexts
12 Thioredoxin system (Trx / TrxR) ↓ functional reserve / overload (R→G) ↔ preserved capacity (G) R, G Parallel antioxidant system stress Useful when GSH-only does not explain redox phenotype 
Time-Scale Flag: TSF = P / R / G
  P: 0–30 min (physical / electron / radical effects)
  R: 30 min–3 hr (redox signaling & stress response)
  G: >3 hr (gene-regulatory adaptation)
MPTP: opening represents a mitochondrial commitment event integrating ROS and Ca²⁺ stress; sustained opening indicates irreversible bioenergetic failure.
Scientific Papers found: Click to Expand⟱
2256- MF,  HPT,    Effects of exposure to repetitive pulsed magnetic stimulation on cell proliferation and expression of heat shock protein 70 in normal and malignant cells
- in-vitro, BC, MCF-7 - in-vitro, Cerv, HeLa - in-vitro, Nor, HBL-100
HSP70/HSPA5↑, HSP70/HSPA5∅,
3466- MF,    The effect of magnetic fields on tumor occurrence and progression: Recent advances
- Review, Var, NA
angioG↓, ROS↝, EGFR↝, TumCG↓,
3467- MF,    Pulsed Magnetic Field Induces Angiogenesis and Improves Cardiac Function of Surgically Induced Infarcted Myocardium in Sprague-Dawley Rats
- in-vivo, Nor, NA
*angioG↑, *cardioP↑,
3468- MF,    An integrative review of pulsed electromagnetic field therapy (PEMF) and wound healing
- Review, NA, NA
*other↑, *necrosis↓, *IL6↑, *TGF-β↑, *iNOS↑, *MMP2↑, *MCP1↑, *HO-1↑, *Inflam↓, *IL1β↓, *IL6↓, *TNF-α↓, *BioAv↑, eff⇅, DNAdam↑, Apoptosis↑, ROS↑, TumCP↓, *ROS↓, *FGF↑,
3469- MF,    Pulsed Electromagnetic Fields (PEMF)—Physiological Response and Its Potential in Trauma Treatment
- Review, NA, NA
*eff↑, *eff↝, *other↑, Ca+2↑, ROS↑, HSP70/HSPA5↑, *NOTCH↑, *HEY1↑, *p38↑, *MAPK↑,
3470- MF,    Pulsed electromagnetic fields inhibit IL-37 to alleviate CD8+ T cell dysfunction and suppress cervical cancer progression
- in-vitro, Cerv, HeLa
TNF-α↑, IL6↑, ROS↑, Apoptosis↑, TumCP↓, TumCMig↓, TumCI↓,
3471- MF,    The prevention effect of pulsed electromagnetic fields treatment on senile osteoporosis in vivo via improving the inflammatory bone microenvironment
- in-vivo, Nor, NA
*BMD↑, *NLRP3↓, *proCasp1↓, *cl‑Casp1↓, *IL1β↓, *GSDMD↓,
3472- MF,    Pulsed electromagnetic field alleviates synovitis and inhibits the NLRP3/Caspase-1/GSDMD signaling pathway in osteoarthritis rats
- in-vivo, ostP, NA
*Inflam↓, *NLRP3↓, *Casp1↓, *GSDMD?,
3473- MF,    Therapeutic use of pulsed electromagnetic field therapy reduces prostate volume and lower urinary tract symptoms in benign prostatic hyperplasia
- Human, BPH, NA
*Inflam↓, *Dose↝, *other?,
2247- MF,    Effects of Pulsed Electromagnetic Field Treatment on Skeletal Muscle Tissue Recovery in a Rat Model of Collagenase-Induced Tendinopathy: Results from a Proteome Analysis
- in-vivo, Nor, NA
*Glycolysis↓, *LDHB↑, *NAD↑, *ATP↑, *antiOx↑, *ROS↑, *YAP/TEAD↑, *PGC-1α↑, *TCA↑, *FAO↑, *OXPHOS↑,
2238- MF,    Electromagnetic fields act via activation of voltage-gated calcium channels to produce beneficial or adverse effects
- Review, Var, NA
*BMD↑, *VGCC↑, *Ca+2↑, *NO↑, *eff↓,
2239- MF,    Time-varying magnetic fields increase cytosolic free Ca2+ in HL-60 cells
- in-vitro, AML, HL-60
Ca+2↑, eff↝,
2240- MF,    Pulsed electromagnetic field induces Ca2+-dependent osteoblastogenesis in C3H10T1/2 mesenchymal cells through the Wnt-Ca2+/Wnt-β-catenin signaling pathway
- in-vitro, Nor, C3H10T1/2
*Ca+2↑, *Diff↑, *BMD↑, *Wnt↑, *β-catenin/ZEB1↑, *eff↝,
2241- MF,    Pulsed electromagnetic therapy in cancer treatment: Progress and outlook
- Review, Var, NA
other↝, p‑ERK↝, P53↝, Cyt‑c↝, OXPHOS↑, Apoptosis↑, ROS↑,
2242- MF,    Electromagnetic stimulation increases mitochondrial function in osteogenic cells and promotes bone fracture repair
- in-vitro, Nor, NA
*MMP↑, *Diff↑, *OXPHOS↑, *BMD↑, ATP∅,
2243- MF,    Pulsed electromagnetic fields increase osteogenetic commitment of MSCs via the mTOR pathway in TNF-α mediated inflammatory conditions: an in-vitro study
- in-vitro, Nor, NA
*eff↑, *mTOR↑, *Akt↑, *PKA↑, *MAPK↑, *ERK↑, *BMP2↑, *Diff↑, *PKCδ↓, *VEGF↑, *IL10↑,
2244- MF,    Little strokes fell big oaks: The use of weak magnetic fields and reactive oxygen species to fight cancer
- Review, Var, NA
RPM↑, Glycolysis∅, ROS↑, ChemoSen↑, RadioS↑, selectivity↑,
2245- MF,    Quantum based effects of therapeutic nuclear magnetic resonance persistently reduce glycolysis
- in-vitro, Nor, NIH-3T3
Warburg↓, Hif1a↓, *Hif1a∅, Glycolysis↓, *lactateProd↓, *ADP:ATP↓, Pyruv↓, ADP:ATP↓, *PPP↓, *mt-ROS↑, *ROS↓, RPM↑, *ECAR↓,
2246- MF,    The Use of Pulsed Electromagnetic Field to Modulate Inflammation and Improve Tissue Regeneration: A Review
- in-vitro, Nor, NA
*Inflam↓, *IL1↓, *IL6↓, IL17↓, *TNF-α↓,
522- MF,    Low Magnetic Field Exposure Alters Prostate Cancer Cell Properties
- in-vitro, Pca, PC3
MMP2↑, MMP9↑, miR-21↑, miR-155↑, miR-210↑, miR-200c↓, miR-126↓,
2248- MF,    Magnetic fields modulate metabolism and gut microbiome in correlation with Pgc-1α expression: Follow-up to an in vitro magnetic mitohormetic study
- in-vivo, Nor, NA
*PGC-1α↑, *GutMicro↑, *FAO↓, *Insulin↓,
2249- MF,    Pulsed electromagnetic fields modulate energy metabolism during wound healing process: an in vitro model study
- in-vitro, Nor, L929
*TumCMig↑, *tumCV↑, *Glycolysis↑, *ROS↓, *mitResp↓, *other↝, *OXPHOS↓, *pH↑, *antiOx↑, *PFKM↑, *PFKL↑, *PKM2↑, *HK2↑, *GLUT1↑, *GPx1↑, *GPx4↑, *SOD1↑,
2250- MF,  MNPs,    Confronting stem cells with surface-modified magnetic nanoparticles and low-frequency pulsed electromagnetic field
- Review, NA, NA
*Ca+2↑, *Dose↝, *BioAv↓,
2251- MF,  Rad,    BEMER Electromagnetic Field Therapy Reduces Cancer Cell Radioresistance by Enhanced ROS Formation and Induced DNA Damage
- in-vitro, Lung, A549 - in-vitro, HNSCC, UTSCC15 - in-vitro, CRC, DLD1 - in-vitro, PC, MIA PaCa-2
RadioS↑, DNAdam↑, ROS↑, ChemoSen∅, Pyruv↓, ADP:ATP↓, ROS↑,
2252- MF,  HPT,    Cellular Response to ELF-MF and Heat: Evidence for a Common Involvement of Heat Shock Proteins?
- Review, NA, NA
HSPs∅, *HSPs↑, eff↝, *eff↑, eff↑, eff↓,
2253- MF,    Low-frequency pulsed electromagnetic field promotes functional recovery, reduces inflammation and oxidative stress, and enhances HSP70 expression following spinal cord injury
- in-vivo, Nor, NA
*Inflam↓, *TNF-α↓, *IL1β↓, *NF-kB↓, *iNOS↓, *ROS↓, Catalase↑, *SOD↑, *HSP70/HSPA5↑, *neuroP↑, *motorD↑, *antiOx↑,
2254- MF,    Effect of 60 Hz electromagnetic fields on the activity of hsp70 promoter: an in vivo study
- in-vivo, Nor, NA
*HSP70/HSPA5↑, HSP70/HSPA5↑,
2255- MF,    Pulsed Electromagnetic Fields Induce Skeletal Muscle Cell Repair by Sustaining the Expression of Proteins Involved in the Response to Cellular Damage and Oxidative Stress
- in-vitro, Nor, SkMC
*HSP70/HSPA5↑, *Apoptosis↓, *Inflam↓, *Trx↓, *PONs↓, *SOD2↓, *TumCG↑, *Diff↑, *HIF2a↑, *Cyt‑c↑, P21↑,
192- MF,    The use of magnetic fields in treatment of patients with rheumatoid arthritis. Review of the literature
- Review, Arthritis, NA
*Dose↝, Pain↓, Inflam↓, Sleep↑,
499- MF,    The Effect of Pulsed Electromagnetic Fields on Angiogenesis
- Review, NA, NA
angioG↑, VEGF↑, VGCC↑,
498- MF,    Stimulation of osteogenic differentiation in human osteoprogenitor cells by pulsed electromagnetic fields: an in vitro study
- in-vitro, NA, NA
Calcium↑, MMP1↑, MMP3↑, BMPs↑,
497- MF,    In Vitro and in Vivo Study of the Effect of Osteogenic Pulsed Electromagnetic Fields on Breast and Lung Cancer Cells
- vitro+vivo, NA, MCF-7 - vitro+vivo, NA, A549
TumCG↓, TumVol↓, Casp3↑, Casp7↑, Apoptosis↑, DNAdam↑, TumCCA↑, ChemoSen↑, EPR↑,
496- MF,    Low-Frequency Magnetic Fields (LF-MFs) Inhibit Proliferation by Triggering Apoptosis and Altering Cell Cycle Distribution in Breast Cancer Cells
- in-vitro, BC, MCF-7 - in-vitro, BC, ZR-75-1 - in-vitro, BC, T47D - in-vitro, BC, MDA-MB-231
ROS↑, PI3K↓, Akt↓, GSK‐3β↑, Apoptosis↑, cl‑PARP↑, cl‑Casp3↑, BAX↑, Bcl-2↓, CycB/CCNB1↓, TumCCA↑, p‑Akt↓, TumCP↓, selectivity↑, eff↓,
495- MF,    How a High-Gradient Magnetic Field Could Affect Cell Life
- in-vitro, NA, HeLa
Apoptosis↑, CellMemb↑,
494- MF,    Effects of Various Densities of 50 Hz Electromagnetic Field on Serum IL-9, IL-10, and TNF-α Levels
- in-vivo, NA, NA
IL9↓, TNF-α↓,
493- MF,    Extremely low-frequency electromagnetic field induces acetylation of heat shock proteins and enhances protein folding
- in-vitro, NA, HEK293 - in-vitro, Liver, AML12
ATP↑, HSP70/HSPA5↓, HSP90↓,
492- MF,    Weak electromagnetic fields (50 Hz) elicit a stress response in human cells
- in-vitro, AML, HL-60
HSP70/HSPA5↑,
491- MF,    Pre-exposure of neuroblastoma cell line to pulsed electromagnetic field prevents H2 O2 -induced ROS production by increasing MnSOD activity
- in-vitro, neuroblastoma, SH-SY5Y
*Dose∅, *ROS↓,
517- MF,  Rad,    Therapeutic Electromagnetic Field (TEMF) and gamma irradiation on human breast cancer xenograft growth, angiogenesis and metastasis
- in-vivo, NA, MDA-MB-231
TumMeta↓, TumCG↓,
490- MF,    Extremely Low Frequency Magnetic Field (ELF-MF) Exposure Sensitizes SH-SY5Y Cells to the Pro-Parkinson's Disease Toxin MPP(.)
- in-vitro, Park, SH-SY5Y
ROS↑,
489- MF,    Time-varying magnetic fields of 60 Hz at 7 mT induce DNA double-strand breaks and activate DNA damage checkpoints without apoptosis
- in-vitro, NA, HeLa - in-vitro, NA, IMR90
DNAdam↑,
488- MF,    Repetitive exposure to a 60-Hz time-varying magnetic field induces DNA double-strand breaks and apoptosis in human cells
- in-vitro, NA, HeLa - in-vitro, NA, IMR90
DNAdam↑, p‑γH2AX↑, Chk2↑, p38↑, Apoptosis↑,
487- MF,    Extremely Low-Frequency Electromagnetic Fields Cause G1 Phase Arrest through the Activation of the ATM-Chk2-p21 Pathway
- in-vitro, NMSC, HaCaT
ATM↑, Chk2↑, P21↑, TumCCA↑,
486- MF,    mTOR Activation by PI3K/Akt and ERK Signaling in Short ELF-EMF Exposed Human Keratinocytes
- in-vitro, Nor, HaCaT
*mTOR↑, *PI3K↑, *Akt↑, *p‑ERK↑, *other↑, *p‑JNK↑, *p‑P70S6K↑,
194- MF,    Electromagnetic Field as a Treatment for Cerebral Ischemic Stroke
- Review, Stroke, NA
*BAD↓, *BAX↓, *Casp3↓, *Bcl-xL↑, *p‑Akt↑, *MMP9↓, *p‑ERK↑, *HIF-1↓, *ROS↓, *VEGF↑, *Ca+2↓, *SOD↑, *IL2↑, *p38↑, *HSP70/HSPA5↑, *Apoptosis↓, *ROS↓, *NO↓,
196- MF,    Mechanism for action of electromagnetic fields on cells
- in-vitro, Nor, NA
*other↑, *Ca+2↝,
197- MF,    A mechanism for action of oscillating electric fields on cells
- Study, Nor, NA
*other↑,
501- MF,    Low Intensity and Frequency Pulsed Electromagnetic Fields Selectively Impair Breast Cancer Cell Viability
- in-vitro, BC, MCF-7 - in-vitro, Nor, MCF10
Apoptosis↑, *toxicity↓, ChemoSen↑, chemoP↑, selectivity↑, DNAdam↑,
518- MF,    Moderate and strong static magnetic fields directly affect EGFR kinase domain orientation to inhibit cancer cell proliferation
- in-vitro, NA, HCT116
EGFR↓, p‑EGFR↓,
515- MF,    Pulsed Low-Frequency Magnetic Fields Induce Tumor Membrane Disruption and Altered Cell Viability
- in-vitro, Lung, A549
CellMemb↑, TumCP↓,

Showing Research Papers: 51 to 100 of 262
Prev Page 2 of 6 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 262

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

Catalase↑, 1,   OXPHOS↑, 1,   ROS↑, 9,   ROS↝, 1,   RPM↑, 2,  

Mitochondria & Bioenergetics ⓘ

ADP:ATP↓, 2,   ATP↑, 1,   ATP∅, 1,  

Core Metabolism/Glycolysis ⓘ

Glycolysis↓, 1,   Glycolysis∅, 1,   Pyruv↓, 2,   Warburg↓, 1,  

Cell Death ⓘ

Akt↓, 1,   p‑Akt↓, 1,   Apoptosis↑, 8,   BAX↑, 1,   Bcl-2↓, 1,   Casp3↑, 1,   cl‑Casp3↑, 1,   Casp7↑, 1,   Chk2↑, 2,   Cyt‑c↝, 1,   p38↑, 1,  

Transcription & Epigenetics ⓘ

miR-21↑, 1,   other↝, 1,  

Protein Folding & ER Stress ⓘ

HSP70/HSPA5↓, 1,   HSP70/HSPA5↑, 4,   HSP70/HSPA5∅, 1,   HSP90↓, 1,   HSPs∅, 1,  

DNA Damage & Repair ⓘ

ATM↑, 1,   DNAdam↑, 6,   P53↝, 1,   cl‑PARP↑, 1,   p‑γH2AX↑, 1,  

Cell Cycle & Senescence ⓘ

CycB/CCNB1↓, 1,   P21↑, 2,   TumCCA↑, 3,  

Proliferation, Differentiation & Cell State ⓘ

p‑ERK↝, 1,   GSK‐3β↑, 1,   PI3K↓, 1,   TumCG↓, 3,   VGCC↑, 1,  

Migration ⓘ

Ca+2↑, 2,   miR-155↑, 1,   miR-200c↓, 1,   MMP1↑, 1,   MMP2↑, 1,   MMP3↑, 1,   MMP9↑, 1,   TumCI↓, 1,   TumCMig↓, 1,   TumCP↓, 4,   TumMeta↓, 1,  

Angiogenesis & Vasculature ⓘ

angioG↓, 1,   angioG↑, 1,   EGFR↓, 1,   EGFR↝, 1,   p‑EGFR↓, 1,   EPR↑, 1,   Hif1a↓, 1,   miR-126↓, 1,   miR-210↑, 1,   VEGF↑, 1,  

Barriers & Transport ⓘ

CellMemb↑, 2,  

Immune & Inflammatory Signaling ⓘ

IL17↓, 1,   IL6↑, 1,   IL9↓, 1,   Inflam↓, 1,   TNF-α↓, 1,   TNF-α↑, 1,  

Drug Metabolism & Resistance ⓘ

ChemoSen↑, 3,   ChemoSen∅, 1,   eff↓, 2,   eff↑, 1,   eff⇅, 1,   eff↝, 2,   RadioS↑, 2,   selectivity↑, 3,  

Clinical Biomarkers ⓘ

BMPs↑, 1,   Calcium↑, 1,   EGFR↓, 1,   EGFR↝, 1,   p‑EGFR↓, 1,   IL6↑, 1,  

Functional Outcomes ⓘ

chemoP↑, 1,   Pain↓, 1,   Sleep↑, 1,   TumVol↓, 1,  
Total Targets: 89

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 3,   GPx1↑, 1,   GPx4↑, 1,   HO-1↑, 1,   OXPHOS↓, 1,   OXPHOS↑, 2,   ROS↓, 7,   ROS↑, 1,   mt-ROS↑, 1,   SOD↑, 2,   SOD1↑, 1,   SOD2↓, 1,   Trx↓, 1,  

Mitochondria & Bioenergetics ⓘ

ADP:ATP↓, 1,   ATP↑, 1,   Insulin↓, 1,   mitResp↓, 1,   MMP↑, 1,   PGC-1α↑, 2,  

Core Metabolism/Glycolysis ⓘ

ECAR↓, 1,   FAO↓, 1,   FAO↑, 1,   Glycolysis↓, 1,   Glycolysis↑, 1,   HK2↑, 1,   lactateProd↓, 1,   LDHB↑, 1,   NAD↑, 1,   PFKL↑, 1,   PFKM↑, 1,   PKM2↑, 1,   PONs↓, 1,   PPP↓, 1,   TCA↑, 1,  

Cell Death ⓘ

Akt↑, 2,   p‑Akt↑, 1,   Apoptosis↓, 2,   BAD↓, 1,   BAX↓, 1,   Bcl-xL↑, 1,   BMP2↑, 1,   Casp1↓, 1,   cl‑Casp1↓, 1,   proCasp1↓, 1,   Casp3↓, 1,   Cyt‑c↑, 1,   GSDMD?, 1,   GSDMD↓, 1,   HEY1↑, 1,   iNOS↓, 1,   iNOS↑, 1,   p‑JNK↑, 1,   MAPK↑, 2,   necrosis↓, 1,   p38↑, 2,   YAP/TEAD↑, 1,  

Transcription & Epigenetics ⓘ

other?, 1,   other↑, 5,   other↝, 1,   tumCV↑, 1,  

Protein Folding & ER Stress ⓘ

HSP70/HSPA5↑, 4,   HSPs↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

Diff↑, 4,   ERK↑, 1,   p‑ERK↑, 2,   FGF↑, 1,   mTOR↑, 2,   NOTCH↑, 1,   p‑P70S6K↑, 1,   PI3K↑, 1,   TumCG↑, 1,   VGCC↑, 1,   Wnt↑, 1,  

Migration ⓘ

Ca+2↓, 1,   Ca+2↑, 3,   Ca+2↝, 1,   MMP2↑, 1,   MMP9↓, 1,   PKA↑, 1,   PKCδ↓, 1,   TGF-β↑, 1,   TumCMig↑, 1,   β-catenin/ZEB1↑, 1,  

Angiogenesis & Vasculature ⓘ

angioG↑, 1,   HIF-1↓, 1,   Hif1a∅, 1,   HIF2a↑, 1,   NO↓, 1,   NO↑, 1,   VEGF↑, 2,  

Barriers & Transport ⓘ

GLUT1↑, 1,  

Immune & Inflammatory Signaling ⓘ

IL1↓, 1,   IL10↑, 1,   IL1β↓, 3,   IL2↑, 1,   IL6↓, 2,   IL6↑, 1,   Inflam↓, 6,   MCP1↑, 1,   NF-kB↓, 1,   TNF-α↓, 3,  

Cellular Microenvironment ⓘ

pH↑, 1,  

Protein Aggregation ⓘ

NLRP3↓, 2,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 1,   BioAv↑, 1,   Dose↝, 3,   Dose∅, 1,   eff↓, 1,   eff↑, 3,   eff↝, 2,  

Clinical Biomarkers ⓘ

BMD↑, 4,   GutMicro↑, 1,   IL6↓, 2,   IL6↑, 1,  

Functional Outcomes ⓘ

cardioP↑, 1,   motorD↑, 1,   neuroP↑, 1,   toxicity↓, 1,  
Total Targets: 118

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:172  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page